Ortin Laboratories Ltd - 539287 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sanka Venkata Ratnamma Ortin Laboratories Ltd - 539287 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Balaji Venkateswarlu Sanka Ortin Laboratories Ltd - 539287 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sanka Srinivas Kumar Ortin Laboratories Ltd - 539287 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sanka Venkata Sujatha Ortin Laboratories Ltd - 539287 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sanka Murali Krishna Murthy Ortin Laboratories Ltd - 539287 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication of Financial Results for Fourth quarter and Year ended 31.03.2023 Ortin Laboratories Ltd - 539287 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for the year ended March 31, 2023 Ortin Laboratories Ltd - 539287 - Audited Financial Results For The Quarter And Year Ended March 31, 2023
Audited Financial Results for the quarter and year ended March 31, 2023 Ortin Laboratories Ltd - 539287 - Board Meeting Intimation for Consideration Of Audited Financial Results For The Quarter And Year Ended 31.03.2023
Ortin Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2023 ,inter alia, to consider and approve Audited Financial Results For The Quarter And Year Ended 31.03.2023